Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[e]isoindole α1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia

Journal of Medicinal Chemistry
2001.0

Abstract

In search of a uroselective alpha1A subtype selective antagonist, a novel series of 6-OMe hexahydrobenz[e]isoindoles attached to a bicyclic heterocyclic moiety via a two-carbon linker was synthesized. It was found that in contrast to the previously described series of tricyclic heterocycles,(1) this bicyclic series has very specific requirements for the heterocyclic attachments. The most important structural features contributing to the alpha1A/alpha1B selectivity of these compounds were identified. In vitro functional assays for the alpha1 adrenoceptor subtypes were used to further characterize the most selective compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity. Compound 48 showed the highest degree of selectivity in the radioligand binding assays (56-fold), in the in vitro functional tests (80-fold), and for in vivo prostate selectivity (960-fold).

Knowledge Graph

Similar Paper

Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[e]isoindole α<sub>1A</sub> Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia
Journal of Medicinal Chemistry 2001.0
Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α<sub>1A</sub> Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
Journal of Medicinal Chemistry 2000.0
(Phenylpiperazinyl)cyclohexylureas: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)
Bioorganic &amp; Medicinal Chemistry Letters 2008.0
Synthesis and Pharmacological Characterization of 3-[2-((3aR,9bR)-cis-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1H- benz[e]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-d]pyrimidine- 2,4(1H,3H)-dione (A-131701):  A Uroselective α<sub>1A</sub> Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia
Journal of Medicinal Chemistry 1997.0
(Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)
Bioorganic &amp; Medicinal Chemistry Letters 2007.0
Design and Synthesis of Novel α<sub>1a</sub> Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia
Journal of Medicinal Chemistry 1998.0
(Arylpiperazinyl)cyclohexylsufonamides: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS)
Bioorganic &amp; Medicinal Chemistry Letters 2007.0
In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α<sub>1A</sub> Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia
Journal of Medicinal Chemistry 2000.0
Design and synthesis of selective α1B adrenoceptor antagonists
Bioorganic &amp; Medicinal Chemistry Letters 2006.0
Synthesis and Structure−Activity Studies on N-[5-(1H-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidazole-Containing α<sub>1A</sub>-Adrenoceptor Agonist
Journal of Medicinal Chemistry 2004.0